Eighth Cyberknife System In South Korea Installed And Treating Patients

< BACK TO COMPANY starstarstarstarstar   Business - Company Press Release
28th October 2010, 03:23am - Views: 1073






Misc Miscellaneous Accuray Incorporated 2 image








MEDIA RELEASE PR41919


Eighth CyberKnife System in South Korea Installed and Treating Patients


SUNNYVALE, Calif., Oct. 27 /PRNewswire-AsiaNet/ --


         Installation at Korea Cancer Care Hospital Marks First Hospital

                 in Asia with Two CyberKnife Systems in Use


    Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of

radiosurgery, today announced that the Korea Cancer Care Hospital (KCCH) in

Seoul, South Korea has installed its second CyberKnife(R) Robotic

Radiosurgery System, marking the first hospital in the country - and Asia -

to have two CyberKnife Systems in use.


    The recently acquired CyberKnife System is located at the Asia Cancer

Center (ACC), the new cancer hospital of KCCH located in Busan. It represents

the eighth CyberKnife System in South Korea and the country's first equipped

with a linear accelerator capable of delivering a dose rate of 1,000MU

(monitor unit) per minute, which improves the system's efficiency.


    "We are very pleased to be the first hospital in South Korea with two

CyberKnife Systems in use," said Dr. Kwang Mo Yang, Chief of Cancer Research

Division and Radiation Oncologist at ACC. "The CyberKnife System, a

state-of-the-art form of cancer care will enable us to expand our radiation

offerings to patients who may not have been able to tolerate other treatments

or have medically or surgically inoperable tumors. With this additional

capability at ACC, the CyberKnife System is a definite asset for our

treatment program, offering an alternative to our patients and establishing

the ACC's role as 'The First Medical Hub of Asia.'"


    "We are very proud that the CyberKnife System has been serving Korean

patients and KCCH, one of the most prestigious cancer care and research

institutes, for eight years," said Cynthia Chan, Director of Marketing,

Accuray APAC. "CyberKnife technology is increasingly accepted by the medical

community in Korea. The second CyberKnife System with the newest product

enhancements now being used at ACC not only broadens patient access, but also

contributes to the clinical development of radiosurgery and high precision

radiotherapy in Korea."


    Korea Cancer Care Hospital has been one of the nation's leading cancer

centers for over four decades. In 2002, KCCH installed their first CyberKnife

System and established their medical complex composed of a hospital, research

center, and the national radiation emergency medical center. Today, the

second CyberKnife System installed treating patients at ACC, the KCCH's Busan

branch, will help to play an important role in enhancing medical welfare,

improving research of radiation medicine, and providing world class

treatment.


    About Asia Cancer Center

    ACC is a 300 bed facility offering a specialized cancer prevention

center, research center and radiation emergency medical center. ACC intends

to offer facilities such as a sea park, resort and golf course with the

vision to establish "The First Medical Hub of Asia" offering tourism,

recuperation and treatment all in one place. ACC will establish ten cancer

sub-centers specializing in stomach, lung, liver, colorectal, breast,

cervical and thyroid cancers, as well as clinical service center and cancer

prevention center. A series of sensitivity treatments such as psychology,

languages, fine arts and ceramic arts will also be provided to assist in the

Misc Miscellaneous Accuray Incorporated 3 image

complete rapid recovery of patients.


    About the CyberKnife(R) Robotic Radiosurgery System

    The CyberKnife Robotic Radiosurgery System is the world's only robotic

radiosurgery system designed to treat tumors anywhere in the body

non-invasively. Using continual image guidance technology and computer

controlled robotic mobility, the CyberKnife System automatically tracks,

detects and corrects for tumor and patient movement in real-time throughout

the treatment. This enables the CyberKnife System to deliver high-dose

radiation with pinpoint precision, which minimizes damage to surrounding

healthy tissue and eliminates the need for invasive head or body

stabilization frames.


    About Accuray

    Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a

global leader in the field of radiosurgery dedicated to providing an improved

quality of life and a non-surgical treatment option for those diagnosed with

cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery

System, which extends the benefits of radiosurgery to include extracranial

tumors, including those in the spine, lung, prostate, liver and pancreas. To

date, the CyberKnife System has been used to deliver more than 100,000

treatments worldwide and currently more than 206 systems have been installed

in leading hospitals in the Americas, Europe and Asia. For more information,



    Safe Harbor Statement

    The foregoing may contain certain forward-looking statements that involve

risks and uncertainties, including uncertainties associated with the medical

device industry. Except for the historical information contained herein, the

matters set forth in this press release, including statements relating to

multiple units, patient treatment volumes, clinical acceptance, clinical

benefits and investments in radiosurgery are forward-looking statements

within the meaning of the "safe harbor" provisions of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements speak only as of

the date the statements are made and are based on information available at

the time those statements are made and/or management's good faith belief as

of that time with respect to future events. You should not put undue reliance

on any forward-looking statements. Important factors that could cause actual

performance and results to differ materially from the forward-looking

statements we make include: market acceptance of products; competing

products, the combination of our products with complementary technology; and

other risks detailed from time to time under the heading "Risk Factors" in

our report on Form 10-K for the 2010 fiscal year which has been filed with

the Securities and Exchange Commission filed on August 31, 2010. The

Company's actual results of operations may differ significantly from those

contemplated by such forward-looking statements as a result of these and

other factors. We assume no obligation to update forward-looking statements

to reflect actual performance or results, changes in assumptions or changes

in other factors affecting forward-looking information, except to the extent

required by applicable securities laws.


SOURCE: Accuray Incorporated

    

CONTACT: Stephanie Tomei, Senior Manager, Marketing Communications of

         Accuray Incorporated, 

         +1-408-789-4234, 

         stomei@accuray.com, or 


         Kaman Ng, Marcom Manager, Accuray Asia, 

         +852 2247-8622, 

         kng@accuray.com




To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article